RS63446B1 - Kompozicije za lečenje amiloidoze - Google Patents

Kompozicije za lečenje amiloidoze

Info

Publication number
RS63446B1
RS63446B1 RS20220716A RSP20220716A RS63446B1 RS 63446 B1 RS63446 B1 RS 63446B1 RS 20220716 A RS20220716 A RS 20220716A RS P20220716 A RSP20220716 A RS P20220716A RS 63446 B1 RS63446 B1 RS 63446B1
Authority
RS
Serbia
Prior art keywords
compositions
treating amyloidosis
amyloidosis
treating
Prior art date
Application number
RS20220716A
Other languages
English (en)
Inventor
Gene G Kinney
Spencer D Guthrie
Martin Koller
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of RS63446B1 publication Critical patent/RS63446B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20220716A 2016-06-30 2017-06-30 Kompozicije za lečenje amiloidoze RS63446B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30
EP17740200.5A EP3478713B1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis
PCT/US2017/040289 WO2018005967A1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis

Publications (1)

Publication Number Publication Date
RS63446B1 true RS63446B1 (sr) 2022-08-31

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220716A RS63446B1 (sr) 2016-06-30 2017-06-30 Kompozicije za lečenje amiloidoze

Country Status (14)

Country Link
US (2) US20190169280A1 (sr)
EP (1) EP3478713B1 (sr)
JP (2) JP2019519584A (sr)
DK (1) DK3478713T3 (sr)
ES (1) ES2914781T3 (sr)
HR (1) HRP20220979T8 (sr)
HU (1) HUE059400T2 (sr)
LT (1) LT3478713T (sr)
MA (1) MA45552A (sr)
PL (1) PL3478713T3 (sr)
PT (1) PT3478713T (sr)
RS (1) RS63446B1 (sr)
SI (1) SI3478713T1 (sr)
WO (1) WO2018005967A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019240413A1 (en) * 2018-03-23 2020-10-08 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
SG11202108767PA (en) * 2019-02-12 2021-09-29 Prothena Biosciences Ltd Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
US11692024B2 (en) * 2019-03-05 2023-07-04 Prothena Biosciences Limited Methods of treating AL amyloidosis
WO2021041884A1 (en) * 2019-08-30 2021-03-04 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
PE20230839A1 (es) * 2020-06-22 2023-05-19 Ngm Biopharmaceuticals Inc Agentes de union a lair-1 y metodos para su uso
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7928203B2 (en) 2007-12-28 2011-04-19 Elan Pharmaceuticals, Inc. Chimeric, humanized, or human antibody 2A4
AU2012328739B2 (en) 2011-10-25 2017-11-30 Prothena Biosciences Limited Antibody formulations and methods

Also Published As

Publication number Publication date
LT3478713T (lt) 2022-06-10
HRP20220979T8 (hr) 2023-02-03
HUE059400T2 (hu) 2022-11-28
PT3478713T (pt) 2022-05-27
EP3478713B1 (en) 2022-05-11
SI3478713T1 (sl) 2022-06-30
ES2914781T3 (es) 2022-06-16
US20190169280A1 (en) 2019-06-06
HRP20220979T1 (hr) 2022-11-11
WO2018005967A1 (en) 2018-01-04
DK3478713T3 (da) 2022-06-20
EP3478713A1 (en) 2019-05-08
US20210079078A1 (en) 2021-03-18
MA45552A (fr) 2019-05-08
PL3478713T3 (pl) 2022-10-10
JP2022121658A (ja) 2022-08-19
JP2019519584A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
IL261792B (en) Preparations
IL260933A (en) Preparations containing tocorsol or its analogues
GB201715639D0 (en) Compositions for wound treatment
LT3377516T (lt) Kompozicija vėžiui gydyti
GB201610156D0 (en) Cliptac compositions
SI3478713T1 (sl) Sestavki za zdravljenje amiloidoze
GB201600075D0 (en) Immunogenci composition
IL265255A (en) Dementia treatment preparations
GB201614799D0 (en) Compositions
EP3443034C0 (en) COMPOSITION
GB201622161D0 (en) Compositions
EP3413873C0 (en) NEW COMPOSITIONS
GB201610628D0 (en) New compositions
LT3519050T (lt) Kompozicijos, skirtos oftalmologinių būklių gydymui
IL246919A0 (en) New preparations for the treatment of mechanical nerve injuries
GB201602658D0 (en) Compositions
IL268715A (en) Preparations for the treatment of acne
GB201614230D0 (en) Compositions
GB201611960D0 (en) Compositions
GB201611851D0 (en) Compositions
GB201510658D0 (en) Compositions for wound treatment
GB201602656D0 (en) Compositions
GB201604899D0 (en) Composition
GB201604900D0 (en) Composition
GB201604341D0 (en) Composition